Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 26, 2025, titled "Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.".
Press Release Nov 26 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a licensing and commercialization agreement with RK Pharma for a novel oncology supportive care product intended for the US market. Under this agreement, RK Pharma will manufacture the product while Zydus will handle the NDA submission and commercialization. The product aims to reduce dosing errors and enhance compliance among healthcare professionals. This partnership reflects Zydus's commitment to delivering high-quality medicines and improving patient care in the US.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
- Press Release Nov 25 2025
- Press Release Nov 14 2025
- Press Release Nov 13 2025
- Press Release Nov 11 2025
Later from Zydus Lifesciences
- Press Release Nov 27 2025
- Press Release Dec 04 2025
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
- Press Release Dec 09 2025
- Press Release Dec 10 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences